JUMPCAN(SH:600566) Xin Lang Cai Jing·2025-10-23 05:34Core Viewpoint - Jichuan Pharmaceutical's stock has experienced a decline in price and trading volume, reflecting a challenging financial performance in recent periods [1][2]. Financial Performance - As of June 30, 2025, Jichuan Pharmaceutical reported a revenue of 2.749 billion yuan, a year-on-year decrease of 31.87% [2]. - The net profit attributable to shareholders for the same period was 724 million yuan, down 45.87% year-on-year [2]. - Year-to-date, the company's stock price has dropped by 8.30%, with a 2.48% decline over the last five trading days and a 10.29% drop over the last 60 days [1]. Shareholder Information - The number of shareholders increased to 44,000, a rise of 4.69% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 4.48% to 20,834 shares [2]. - As of June 30, 2025, the top circulating shareholder, Hong Kong Central Clearing Limited, reduced its holdings by 5.6693 million shares to 13.1874 million shares [3]. Dividend Distribution - Since its A-share listing, Jichuan Pharmaceutical has distributed a total of 9.227 billion yuan in dividends, with 3.931 billion yuan distributed over the last three years [3]. Market Activity - As of October 23, 2023, Jichuan Pharmaceutical's stock was trading at 24.76 yuan per share, with a market capitalization of 22.796 billion yuan [1]. - The stock experienced a net outflow of 8.6451 million yuan in principal funds, indicating a lack of investor confidence [1].